Agendia Raises Double Digit $ Millions in Series A Round for Microarray-Based Cancer Tests

Mar 30, 2004

This story has been updated from an earlier version to include more precise funding information from Agendia.

NEW YORK, GenomeWeb News (March 30) - Dutch cancer diagnostics company Agendia has raised "double digit" millions of dollars in a Series A financing round, the company told GenomeWeb News today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu